Mangrove Partners IM LLC Makes New $1.14 Million Investment in Natera, Inc. $NTRA

Mangrove Partners IM LLC purchased a new position in Natera, Inc. (NASDAQ:NTRA) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,960 shares of the medical research company’s stock, valued at approximately $1,136,000.

A number of other large investors have also bought and sold shares of NTRA. Integrated Wealth Concepts LLC lifted its stake in shares of Natera by 6.6% in the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after buying an additional 96 shares in the last quarter. NewEdge Advisors LLC lifted its stake in shares of Natera by 68.3% in the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after buying an additional 1,847 shares in the last quarter. Focus Partners Wealth lifted its stake in shares of Natera by 8.6% in the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after buying an additional 474 shares in the last quarter. Sivia Capital Partners LLC bought a new position in shares of Natera in the second quarter valued at $298,000. Finally, WINTON GROUP Ltd bought a new position in shares of Natera in the second quarter valued at $558,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 3,405 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $203.69, for a total transaction of $693,564.45. Following the transaction, the insider directly owned 142,295 shares of the company’s stock, valued at $28,984,068.55. This trade represents a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 41,124 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the transaction, the chief executive officer directly owned 108,743 shares in the company, valued at $24,035,465.29. The trade was a 27.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 159,378 shares of company stock valued at $34,640,860 over the last three months. Insiders own 5.05% of the company’s stock.

Natera Price Performance

NTRA opened at $220.11 on Wednesday. The company’s 50-day moving average is $206.92 and its 200 day moving average is $215.57. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36. The firm has a market capitalization of $31.52 billion, a P/E ratio of -135.04 and a beta of 1.56.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. The Goldman Sachs Group assumed coverage on shares of Natera in a research note on Friday, June 5th. They issued a “neutral” rating and a $245.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Tuesday, April 21st. Wolfe Research assumed coverage on shares of Natera in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price objective on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $249.00 price objective on shares of Natera in a research note on Tuesday, May 12th. Finally, Robert W. Baird set a $265.00 price objective on shares of Natera in a research note on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $256.53.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.